Serum Endocan Levels Research Articles

Serum endocan levels in patients with retinal vein occlusion

Serum endocan levels in patients with retinal vein occlusion

Can serum endocan level predict stage of diabetic retinopathy?

Can serum endocan level predict stage of diabetic retinopathy?

The role of endocan and selected pro-inflammatory cytokines in systemic lupus erythematosus.

IntroductionSystemic lupus erythematosus (SLE) is a multisystem inflammatory autoimmune disease with a wide spectrum of clinical manifestations. Cytokines such as interleukin-1 (IL-1) and tumour necrosis factor α (TNF-α) are involved in its pathogenesis. Endocan is a novel marker of endothelial dysfunction and is likely to be engaged in proinflammatory processes in SLE.AimTo determine whether endocan serum concentration in SLE patients vary from healthy controls.Material and methodsThe study included 36 patients with SLE. SLEDAI-2K score was used to assess disease activity. The control group comprised 23 healthy volunteers. ELISA kits were used to assess serum concentrations of endocan, IL-1β, TNF-α, vascular endothelial growth factor (VEGF) and high-sensitivity C reactive protein (hs-CRP).ResultsThe serum concentration of endocan was significantly higher (p < 0.001) in the SLE group than in healthy individuals. A positive correlation was found between serum levels of endocan and IL-1β (r = 0.47, p < 0.05). Active SLE patients (SLEDAI-2K score above 6 points) with an elevated total cholesterol level (above 5.17 mmol/l) were found to have VEGF concentration higher than those with a normal cholesterol level (p < 0.03). No other relevant relationships were found between the serum concentration of endocan, other laboratory parameters, anthropometric features, activity and duration of SLE.ConclusionsA higher serum level of endocan in SLE patients indicates its possible role in the pathogenesis of the disease and reflects endothelial dysfunction. Our findings indicate that endocan could serve as a potential marker of endothelial dysfunction in SLE.

Serum endocan and preoperative systemic inflammatory markers in patients with epilepsy

ObjectiveThe mechanisms underlying epileptogenesis are still a focus of experimental and clinical research. Inflammation and angiogenesis are the two main topics that have been an area of interest recently. The present study assessed serum levels of endocan, an inflammatory and angiogenesis-promoting molecule, and of preoperative inflammatory markers (neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR)) in adult patients undergoing epilepsy surgery. MethodsTwenty-one patients with epilepsy and 21 healthy controls were included. From patients, serum was collected twice: before and within a week after surgery. From controls, serum was collected once. Serum endocan was studied by ELISA and preoperative NLR and PLR were obtained from preoperative hemogram parameters. ResultsPreoperative serum endocan levels in patients were significantly higher than in controls. There was no difference between patients and controls regarding preoperative NLR and PLR. After surgery, serum endocan levels decreased in patients, with no further difference compared to controls. Serum endocan levels, NLR and PLR correlated positively, but not significantly, with epilepsy duration and seizure frequency. ConclusionsAngiogenesis and low-grade inflammation may play a role in the development and progression of epilepsy. We suggest that larger cohort of epilepsy patients with longer-term follow-up should be studied.

An evaluation of biomarkers indicating endothelial cell damage, inflammation and coagulation in children with Henoch-Schönlein purpura

Abstract Objective Henoch-Schönlein purpura (HSP) is characterized by generalized vasculitis. The etiopathogenesis of the disease is unknown, but inflammation and endothelial dysfunction have been held responsible. Therefore, herein we investigated serum levels of biomarkers indicating endothelial cell damage, inflammation and coagulation in children with HSP. Materials and methods Twenty six patients with HSP and 26 healthy children were included in the study. Routine biochemical tests and laboratory parameters showing inflammation, coagulation, and endothelial cell damage were examined in all subjects. Results White blood cell (WBC) number, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), neutrophil/lymphocyte rate (NLR), triglyceride, immunoglobulin A (IgA), and C3 were significantly higher in children with HSP than the controls. HDL and albumin levels were lower in the patients with HSP. Endocan levels were not significantly different between the HSP and control groups (p = 0.884). Serum endocan levels in patients with HSP were inversely correlated only with activated partial thromboplastin time (APTT) (r = −0.485, p = 0.012). Conclusion Coagulation abnormalities and increased acute phase reactants were present in patients with HSP while no difference was determined in endocan levels.

Is Endocan a Novel Diagnostic Marker for the Severity of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants?

IntroductionEndocan levels were found to be associated with severity and mortality of the respiratory system diseases. ObjectiveWe aimed to figure out whether endocan was an important marker for the diagnosis, severity and follow-up of bronchopulmonary dysplasia (BPD). Materials and methodsInfants with moderate/severe BPD, and who required hydrocortisone treatment were included in the study group. Infants without BPD were allocated in the control group. Endocan levels were compared between the control group and the study group, and before and after the treatment in the study group. ResultsA total of 148 infants, 74 infants in the control group and 74 infants in the BPD group, were included. The endocan level was higher in the BPD group than in the control group (P = .001). Endocan levels before treatment in the BPD group was found to be higher than endocan level after treatment (P = .021). ConclusionOur study found that endocan levels increased in moderate/severe BPD. Serum endocan levels may be a safe and novel indicator for the follow-up of response to treatment and the prognosis of the severity of the disease.

Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated hemoglobin (HbA1c) in patients with prediabetes and type 2 diabetes.

IntroductionWe aimed to examine serum endocan level and the summary involvement of dyslipidemia, oxidative stress (OS) and inflammation by calculation of its comprehensive score (i.e. Dyslipidemia-Oxy-Inflammation (DOI) score) in relation to glucoregulation in subjects with prediabetes and overt type 2 diabetes (T2D).Material and methodsA total of 59 patients with prediabetes and 102 patients with T2D were compared with 117 diabetes-free controls. Glycated hemoglobin (HbA1c), inflammation, OS and lipid parameters were measured. Associations of clinical data with HbA1c level were tested with univariate and multivariate logistic ordinal regression analysis. HbA1c as a dependent variable is given at the ordinal level (i.e. < 5.7%; 5.7–6.4%, > 6.4%, respectively).ResultsEndocan was significantly higher in the T2D group than in the controls. As endocan concentration rose by 1 unit, the probability for higher HbA1c concentration increased by more than 3 times (OR = 3.69, 95% CI: 1.84–7.01, p < 0.001). Also, a rise in the dyslipidemia score, oxy score, inflammation score and DOI score by 1 unit increased the probability of higher HbA1c concentration by 19%, 13%, 51% and 11%, respectively. In the models, after adjustment for confounding variables, endocan and DOI score remained independent predictors of HbA1c level.ConclusionsEndocan and DOI score are independently correlated with HbA1c in patients with prediabetes and overt T2D.

The utility of maternal serum endocan level to predict preterm delivery within seven days in patients with threatened preterm labor

Objective The aim of the current study was to determine serum endocan levels in patients with threatened preterm labor and to assign whether endocan levels in patients with true preterm labor who give birth within 7 days differ from those of false preterm labor and uncomplicated pregnancy. Materials and methods This cross-sectional study was conducted on 58 patients diagnosed with threatened preterm labor and 31 healthy pregnant women matched for gestational age. Patients with threatened preterm labor were divided into two groups; preterm delivery (28) and term delivery (30) groups. Maternal serum endocan levels were measured with the use of an enzyme-linked immunosorbent assay kit. Results The median serum endocan level (pg/mL) in patients with threatened preterm labor was significantly higher than that of women with uncomplicated pregnancies (725, IQR 619–823 versus 310, IQR 218–423; p < .001 Figure 1). Subgroup analysis performed among threatened preterm labor group revealed that median serum endocan level (pg/mL) in preterm delivery group was higher compared with the other two groups (preterm 823, IQR 718–905 versus term 637, IQR 590–729 p < .001 and preterm 823, IQR 718–905 versus control 310, IQR 218–423 p < .001). The threshold value of maternal serum endocan level for predicting delivery within 7 days after admission was calculated 655 pg/mL, (the area under curve was 0.934, 95% CI 0.88–0.98, p < .001) with 85.7% sensitivity and 78.7% specificity. The mean cervical length measurement was significantly higher in the control group (p < .001); there was no significant difference in cervical length between the term and preterm delivery groups. Maternal characteristics including age, BMI, gravidity, gestational age at blood sampling, CRP and Hb levels were not significantly different between groups (p > .05). Conclusions The maternal serum endocan level may be a useful marker to define high risk group for preterm delivery in patients with threatened preterm labor and similar cervical length measures.

Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension

ABSTRACTBackground: Endocan is a particular protein of endothelial cells. The purpose of this study was to determine the relationship of serum endocan levels with carotid intima-media thickness (cIMT), inflammation, and microalbuminuria in patients with newly-diagnosed hypertension.Materials-Methods: This prospective study included 61 patients with newly-diagnosed hypertension (HT) and 30 controls. Endocan, microalbuminuria and cIMT measurements were taken from all patients.Results: The serum endocan levels, the mean cIMT and microalbuminuria levels of patients with HT were significantly higher than those of the control group (p < .0001, p = .015 and p < .001, respectively).Conclusion: We found that endocan levels were increased in our study. This increase in endocan levels shows a relation with cIMT and microalbuminuria, which are associated with endothelial dysfunction.

Endocan - a potential diagnostic marker for early onset sepsis in neonates.

Neonatal early onset sepsis assessment is based on the history of pregnancy and delivery and nonspecific clinical signs. None of the biomarkers currently in use for clinical practice has adequate prognostic value, so it is not possible to clearly distinguish neonates with culture-proven sepsis from those with only risk factors or clinical suspicion. Endocan is an endothelial mediator involved in the inflammatory response that is present in low concentrations in the serum of healthy subjects, and in much higher concentrations in patients with SIRS and septic shock. The purpose of this study is to evaluate the utility of serum endocan serum levels as a biomarker for the diagnosis of neonatal early onset sepsis (EOS). Serum endocan concentration was measured in newborns with clinical suspicion of EOS admitted to the Neonatal Intensive Care Unit on day 1, 3 and 7. Serum endocan levels were significantly increased in septic compared to non-septic neonates in the early stages of sepsis (2.43 ± 0.95 vs. 1.77 ± 0.57, p = 0.004), continued to rise up to 72 hours from onset and then decreased by the seventh day under treatment. These results suggest a potential role for endocan as an early marker for diagnosis and follow-up in neonatal EOS. Studies on a larger number of cases are needed in order to establish the practical utility of this molecule as a diagnostic tool for clinical practice.

Relationship between serum endocan levels and clinical follow-up in patients with acute pancreatitis: Can serum endocan be a biomarker for acute pancreatitis?

Giriş ve Amaç: Akut pankreatit seyrinde hastalığın prognozunu tayin etmek için birçok belirteç ve skorlama sistemleri kullanılmaktadır. Bu çalışmada endocan düzeyinin hafif ve şiddetli pankreatit vakalarında C-reaktif protein, Ranson skoru, revize Atlanta skorlaması ve diğer laboratuvar göstergeleri ile ilişkisi karşılaştırılarak prognozu öngörmede öneminin araştırılması planlanmıştır. Gereç ve Yöntem: Çalışmada 50 akut pankreatit hastası prospektif olarak incelendi, başvuru anı, 2. ve 7. günlerde endocan, biyokimyasal parametreler ve C-reaktif protein değerleri ölçüldü. Hastaların şikayet ile başvuru arasındaki zaman, yatış süreleri, skorlama sistemlerine göre pankreatit şiddeti Ranson ve revize Atlanta skoru olarak kaydedildi. Verilerin istatistiksel analizinde SPSS 22.0 paket programı kullanıldı. Bulgular: Hastaların yaş ortalaması 61.36±16.21 yıl olup olup %54’ü kadındı. Ranson skoruna göre 20 olgu (%30) şiddetli pankreatit idi. Endocan değerleri hafif pankreatit grubu ve şiddetli pankreatit grubu ile karşılaştırıldığında başvuru anında, 2. ve 7. günlerde anlamlı sonuç vermemiştir. Revize Atlanta skorlamasına göre sınıflandırılan hasta gruplarının serum endocan ile karşılaştırılmasında istatistiksel açıdan fark görülmedi. Pankreatit şiddeti için 2. gün bakılan C-reaktif protein şiddetli pankreatitte ortalama 95.05 mg/L, hafif pankreatitte ise 77.06 mg/L olarak saptandı. Diğer laboratuvar göstergelerinden alanin aminotransferaz, aspartat aminotransferaz, gama glutamil transferaz, alkalen fosfataz, total bilirübin ve direkt bilirübin hastalığın şiddeti ile korele saptandı. Sonuç: Akut pankreatit prognozu ile endocan arasındaki ilişkiyi daha net ortaya koymak için daha geniş kapsamlı prospektif çalışmalara ihtiyaç vardır.

Koroner Kronik Total Oklüzyonu Olan Hastalarda Serum Endokan Düzeyi ile Koroner Kollateral Dolaşım Arasındaki İlişki

Introduction: Endocan, a dermatan sulfate proteoglycan, is synthesized and secreted by the vascular endothelium. It is involved in the pathogenesis of vascular diseases, organ-specific inflammations, and angiogenesis. The aim of the present study was to investigate the relationship between serum endocan level and development of coronary collateral circulation (CCC) in patients with stable angina pectoris. Patients and Methods: Patients with stable angina with at least one chronic total coronary occlusion (CTO) (n= 44) and who had normal coronary artery (n= 29) were included in the study. Collateral degree was evaluated according to the Rentrop and Cohen's classification. Patients who had grade 0 or 1 collateral filling were included in the poorly developed collateral group (n= 19), and those with grade 2 or 3 collateral filling were included in the well-developed collateral group (n= 23). Results: Endocan levels were significantly higher in patients in the well CCC group than in those in the poor CCC and control groups (p< 0.001). Endocan level is higher in patients with poorly developed CCC than in the control group. Endocan was only found as an independent predictor of well CCC in regression analysis (odds ratio 1.002, 95% confidence interval (CI) 1.001-1.005, p= 0.001). Receiver operating characteristic curve analysis detected an optimal cut-off value for endocan level of 1773.9 ng/L that predicted the presence of well development of CCC with a sensitivity of 84% and specificity of 63% (area under the receiver operating characteristic (ROC) curve: 0.749, 95% CI: 0.654-0.849, p< 0.001). Conclusion: Elevated endocan level is associated with better CCC in patients with CTO. Endocan may play an important role in the development of CCC.

Maternal serum endocan concentrations are elevated in patients with preterm premature rupture of membranes.

Objectives To evaluate the maternal serum endocan levels in pregnant women complicated by preterm premature rupture of membranes (PPROM) and to compare the results with healthy pregnancies. Methods This cohort study included 31 pregnant women with PPROM and 34 gestational age-matched healthy subjects in the third trimester of pregnancy. The blood for analysis was obtained on the day of diagnosis and serum endocan levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit. The pregnant women were observed until the delivery and perinatal data were noted. Results No significant differences regarding maternal age, body mass index, gravidity, parity and gestational age at sampling were observed (P > 0.05). Mean serum endocan level was significantly higher in the PPROM group than in healthy controls (1490 ± 632 pg/mL vs. 972 ± 586 pg/mL, respectively; P: 0.001). Serum endocan concentration was positively correlated with C-reactive protein (CRP) (r = 0.754, P < 0.001) and white blood cells count (WBC) (r = 0.712, P:0.001). The receiver operating characteristic (ROC) curve analysis showed that endocan with a cut-off point of 1198 ng/dL indicated women with PPROM with sensitivity of 64.5% and specificity of 35.1% (area under curve 0.731, confidence interval 0.61-0.85). Conclusion Serum endocan level was significantly elevated in the PPROM patients than in healthy controls. The endocan level may be a useful indicator of endothelial dysfunction/inflammation in PPROM cases.

Is Endocan a Novel Diagnostic Marker for the Severity of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants?

IntroductionEndocan levels were found to be associated with severity and mortality of the respiratory system diseases. ObjectiveWe aimed to figure out whether endocan was an important marker for the diagnosis, severity and follow-up of bronchopulmonary dysplasia (BPD). Materials and methodsInfants with moderate/severe BPD, and who required hydrocortisone treatment were included in the study group. Infants without BPD were allocated in the control group. Endocan levels were compared between the control group and the study group, and before and after the treatment in the study group. ResultsA total of 148 infants, 74 infants in the control group and 74 infants in the BPD group, were included. The endocan level was higher in the BPD group than in the control group (P = .001). Endocan levels before treatment in the BPD group was found to be higher than endocan level after treatment (P = .021). ConclusionOur study found that endocan levels increased in moderate/severe BPD. Serum endocan levels may be a safe and novel indicator for the follow-up of response to treatment and the prognosis of the severity of the disease.

Value of Endocan in Diagnosis and Prognosis of Neonatal Sepsis

Sepsis is one of the most common causes of morbidity and mortality in the newborn. Early diagnosis and treatment is vital to improve outcome. Investigate the possible role for endocan in the diagnosis of neonatal early onst sepsis. 40 children were included in the study, 20 septic and 20 controls, all patients were subjected to full history and clinical assessment and labouratory tests as CBC, CRP and serum level of endocan by ELISA. Results: Neonatal Sepsis group showed significantly higher Endocan when compared to control group (p < 0.001),ROC curve of Endocan level was conducted for discrimination between neonatal sepsis cases and control groups. Endocan showed AUC (AUC=0.758). At cut off value of 21.4, sensitivity was 70%, specificity was 78.3%, PPV was 74.5%, NPV was 68.1%, accuracy was 70.8%. Serum endocan levels are significantly increased in septic compared to non-septic neonates in the early stages of sepsis. We suggest that endocan is an effective, reliable, and promising new biomarker for detecting neonatal sepsis.

Serum endocan level and diastolic functions in the case of lead exposure

Background/aim Lead can cause morphological and functional changes in heart, and inflammation and endothelial dysfunction in vasculature. Endocan, as a novel indicator of endothelial dysfunction, has been used for cardiovascular diseases. This study investigated the relationship between lead exposure, endocan levels, and diastolic functions.Materials and methodsA total of 51 lead-exposed workers without a known cardiovascular disease or risk factors and 54 healthy controls were enrolled. All participants underwent transthoracic echocardiography. Blood lead and serum endocan levels were analyzed.Results Baseline demographic and clinical characteristics were found to be similar between groups. Median blood lead (32 vs 1.5 µg/dL, P < 0.001) and serum endocan levels (67 vs 57.1 pg/mL, P = 0.02) were significantly higher in the lead-exposed group. Serum endocan level showed a positive correlation with blood lead levels (r = 0.404, P = 0.003) in lead-exposed workers. Serum endocan level was an independent risk factor for increased E/E’ ratio (β = 0.704, P = 0.002) and left atrial volume index (β = 1.158, P = 0.011) and higher level of lead in blood was an independent risk factor for increased E wave (β = 8.004, P = 0.022) in lead-exposed workers. Conclusion Worsened diastolic functions may be seen in the course of lead exposure. Due to sharing a similar mechanism, a higher serum level of endocan may be a valuable laboratory clue for impaired diastolic function in this population.

The Relationship Between Serum Endocan Level and Aortic Elastic Properties in Patients With Newly Diagnosed Essential Hypertension

Endothelial dysfunction plays role in the generation of both essential hypertension (EH) and aortic stiffness. We evaluated the relationship between serum endocan level and aortic elastic properties (AEPs) assessed with the aortic strain, aortic distensibility, and aortic stiffness index by echocardiography. Newly diagnosed EH patients (n = 67) and controls (n = 70) were included in the study. The EH group was subdivided into stage 1 and 2 EH groups. A higher endocan level was found in the EH group, compared to the controls (34.2 ± 13.0 vs 24.1 ± 7.3 ng/mL, respectively, P < .001). All the AEP parameters were worse in the EH group, compared to the controls. Further, endocan levels correlated with aortic distensibility (r = -0.305, P < .001) and aortic strain (r = -0.181, P = .038), but not with aortic stiffness index (r = 0.162, P = .064) in the whole study population. Aortic elastic properties deteriorate and serum endocan level increases in patients with EH. Moreover, serum endocan level shows a correlation with deteriorated AEPs, and hence may a surrogate marker of escalating aortic stiffness in patients with newly diagnosed EH.

The relationship between the atherosclerotic cardiovascular disease risk score used in the prediction of cardiovascular disease risk and endocan.

To date, there have been no studies investigating whether or not there is a correlation between the serum endocan level and the atherosclerotic cardiovascular disease (ASCVD) risk score that is frequently used in the determination of the risk of cardiovascular disease. If a single parameter such as endocan can provide reliable results which could be used in the prediction of the cardiovascular disease risk, the workload of the clinician would be lightened. The aim of this study was to investigate whether or not there is an association between the serum endocan level and the ASVCD risk score. This prospective, cross-sectional study included individuals age 40-79 years with risk factors calculated using the ASVCD score and individuals without any of those risk factors. In accordance with ASCVD risk calculation, each participant was questioned with respect to age, gender, height, weight, and lifestyle habits such as smoking, diseases, and medications. Systolic blood pressure, diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and serum endocan levels were measured and recorded. The serum endocan levels and ASCVD scores were compared. The study included 205 individuals, comprising 92 (44.9%) males and 113 (55.1%) females with a mean age of 50.7 ± 7.6 years. The 10-year atherosclerosis risk was determined as mean 6.32% ± 5.9% (range, 0.3%-27.3%). The mean serum endocan level was calculated as 1109.6 ± 1479.7 ng/mL. As the ASCVD risk score increased, no increase was detected in the serum endocan level. The results of the study suggested that the serum endocan level is not suitable for use in place of the ASCVD risk score as a predictor of cardiovascular disease risk.

Relationship between Plasma Endocan Level and Clinical Outcome of Chinese Peritoneal Dialysis Patients

Background: Endocan is associated with endothelial dysfunction. In peritoneal dialysis (PD) patients, cardiovascular disease is a common cause of mortality. We examined the relationship between serum endocan level and clinical outcome of PD patients. Methods: We recruited 193 new PD patients (118 males, mean age 58.8 ± 11.6 years). Serum endocan levels were determined and stratified into tertile 1 (lowest) to 3 (highest). Nutritional status, arterial pulse wave velocity (PWV) and serum C-reactive protein (CRP) levels were measured. The patients were followed for at least 4 years for clinical outcomes. Results: For the whole cohort, patients with higher serum endocan levels had lower serum albumin and subjective global assessment score, higher carotid-femoral PWV, and higher serum CRP. For patients with suboptimal blood pressure (BP) control, cardiovascular event-free survival was 95.0, 95.5, and 78.5% for tertiles 1, 2, and 3 at 60 months respectively (p = 0.019). Multivariate Cox regression analysis showed that serum endocan level was an independent predictor of cardiovascular event-free survival. No association with cardiovascular event-free survival was found for patients with adequate BP control (95.0, 92.3, and 100% for tertile 1, 2, and 3 at 60 months, respectively, p = 0.6). Conclusions: Higher serum endocan level is associated with unfavourable nutritional, arterial and inflammatory conditions in PD patients. In patients with suboptimal BP control, higher serum endocan is also associated with worse cardiovascular outcome.

The role of Endocan as a Prognostic Biomarker in community-acquired pneumonia.

Objective:The aim of this study was to determine the importance of using endocan as a biomarker in deciding the setting of treatment and predicting prognosis in patients with community-acquired pneumonia (CAP).Methods:This prospective, case-control study was conducted at Okmeydani Training and Research Hospital between November 20, 2016 to March 20th 2017. Blood samples were obtained from 63 patients who were admitted to internal medicine clinic due to CAP and 25 volunteers without active infection. Serum samples were centrifuged at 1000G for 15 minutes and stored at -20ºC. Samples were analyzed using human ESM1 (endocan) (Lot No: AK0017MAR0830) (Elabscience, Texas, USA) kit with Robonik (Mumbai, India) ELISA Plate Reader and Washer. Demographic and clinical data of the patients were recorded. CURB-65, qSOFA and Pneumonia Severity Index (PSI) scores were calculated. Primary endpoint of the study was 30-days mortality.Results:Mean serum endocan levels of the study group and the control group were 30.99±3.3 pg/ml and 246.5±49.95pg/ml, respectively. The difference between groups was statistically significant (p<0.005). 30-days mortality rate was 12.7% with eight patients, three of which died subsequently in the ICU. When patients were classified according to PSI and CURB-65 scores, endocan levels of PSI class ≥4 and CURB-65 ≥2 individuals were found to be significantly different than the control group. ROC analysis showed that serum endocan levels less than 64.96pg/ml has 85.2% sensitivity and 83.3% specificity for PSI class ≥4 and 82.4% sensitivity and 55.6% specificity for CURB-65 score ≥2.Conclusion:Serum endocan levels are significantly lower in patients with community-acquired pneumonia than the control group.